����ֱ��

Mumbai, March 13, 2024. The Board of Directors of Sanofi India Limited (“SIL”) today approved an exclusive distribution and promotion agreement between SIL and Emcure Pharmaceuticals Limited (“Emcure”) for SIL����ֱ�� Cardiovascular products in India, effective immediately.

Emcure Pharmaceuticals will exclusively distribute and promote the Company����ֱ�� Cardiovascular (CV) range of products that include well-established brands like Cardace®, Clexane®, Targocid®, Lasix® and Lasilactone®.

While SIL will continue to own, import, and manufacture these brands across Sanofi����ֱ�� plants in India and internationally, Emcure will leverage its strengths to engage healthcare professionals and expand reach of these therapeutic solutions for patients who need them across all areas of India.

Sanofi India����ֱ�� concerned employees will have the opportunity to work at Emcure.

Mr. Rodolfo Hrosz
Managing Director, Sanofi India Limited
“Sanofi has been committed to improving lives of patients in India through its range of products. Sanofi India has many cardiovascular products which are leaders in their respective categories. With Emcure����ֱ�� wide presence across India, our partnership will benefit both HCPs (Healthcare Professionals) and patients by creating the opportunity to maximize the reach of our CV products.”

Mr. Satish Mehta
Chief Executive Officer and Managing Director, Emcure Pharmaceuticals Limited
“At Emcure Pharmaceuticals our competitive advantage lies in our established presence in all major therapeutic areas including cardiology. We’re delighted to have the opportunity to partner with Sanofi India as their range of well-established cardiovascular brands will complement our strong CV portfolio, making it a highly robust offering. Towards this endeavour, Sanofi����ֱ�� relevant team also has the opportunity to join us.”

Sanofi continues to give fresh impetus to its business in the Country with an accelerated growth plan – ‘India for India’, across its pharmaceuticals, specialty, consumer healthcare and vaccines businesses.

Sanofi – in India for India

As Sanofi India, we are in a great place to make a difference. Present in India for nearly seven decades, we have earned the trust of our customers and stakeholders for our commitment to promoting health. As we chase the miracles of science to improve people����ֱ�� lives, we continue to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building.

Our India Charitable Access Program is the country����ֱ�� longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. We conduct clinical trials here so that India can have quicker access to the latest from our global pipeline. Our world-class manufacturing site in Goa produces for people in India and 60+ other countries. Recognized by the ‘Top® Employers Institute’ – a global authority that honours excellence in people practices – for 5 years in a row (since 2019), our local entities include Sanofi India Limited (SIL – listed entity) and Sanofi Healthcare India Pvt. Ltd. (SHIPL).